RxSight Lowers 2026 Sales Guidance, Shares Drop 12.9%
RxSight Inc. (NASDAQ:RXST) announced that its full‑year 2026 sales guidance has been reduced to a range of $110 million to $120 million, narrowing from the prior $120 million‑$135 million outlook. The revision triggered a 12.9% decline in the company’s share price on the day of the announcement.
The company also updated its total 2026 revenue guidance to $140 million‑$160 million, of which $30 million‑$40 million is expected to stem from a recently announced strategic collaboration with Alcon. In its preliminary second‑quarter 2026 results, RxSight projects total revenue of $32 million‑$34 million. This quarter’s estimate incorporates $5 million‑$7 million attributable to the Alcon partnership and roughly $27 million from product sales.
During the quarter, RxSight sold 24,917 units of its Light Adjustable Lens (LAL) and 11 units of its Light Delivery Device, and placed one rental unit. The company cited “meaningful commercial headwinds” in the intraocular lens market, noting more widespread competitive trialing. To mitigate these pressures, RxSight said it is accelerating investments in its sales force and commercial capabilities while maintaining disciplined spending.
Gross‑margin guidance has been raised to a range of 73%‑75%, up from the earlier 70%‑72% outlook. Operating expenses are expected to be at the high end of the previously indicated $150 million‑$160 million range, unchanged from prior guidance. As of June 30, 2026, RxSight reported cash, cash equivalents and short‑term investments of approximately $209 million.
The company outlined its product pipeline, highlighting next‑generation Light Adjustable Lens products—designated LAL, LAL+ and LAL Toric—that are engineered for improved workflow and fewer post‑operative treatments, with intermediate‑term launch timelines.